Eagle Hopes To Build On Bendamustine Success With Injectable Reformulations

With concentrated, lower-volume injectables, the specialty firm is finding larger patient bases for the cancer drug bendamustine and the muscle relaxant dantrolene.

Having succeeded with a more rapid infusion formulation of Teva Pharmaceutical Industries Ltd. cancer drug Treanda (bendamustine), specialty firm Eagle Pharmaceuticals Inc. has proof-of-principle for its business model of reformulating injectable products to broaden their reach.

The firm's next step will be to build up its Ryanodex product by adding an indication for exertional heat stroke and, down the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America